Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Heidi Kay

CEO/Founder

Jericho Sciences

Durham (RTP), North Carolina, United States

1 profile visit

Developing novel antivirals to address public health unmet needs to clear chronic infections and prepare for potential emerging viruses.

My organisation

Jericho Sciences

Jericho Sciences

other

Durham (RTP), North Carolina, United States

Jericho Sciences is developing small molecule antiviral therapeutics to address both chronic virus infections and potential emerging viruses, with current focus on a curative approach for clearing chronic Hepatitis B Virus infection — a leading cause of all liver diseases — with morbidities and mortalities affecting an estimated 3.6 million people in the EU and UK (300 million globally).
Read more

About me

As a PhD chemist, I first worked in academia teaching and researching in chemistry, cancer and other public health areas, including water/wastewater, air pollution and global health. In 2009, I founded an R&D company to transition my anticancer research accomplishments into antiviral applications. Jericho Sciences continues to be funded through highly competitive nondilutive NIH grant awards to develop new antiviral therapies for unmet public health needs. I am passionate about finding beneficial solutions and improving the quality of life.

Social media